Cargando…

Diptoindonesin G, a new Hsp90 drug

Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative diseases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wickramaratne, Anushka, Wickner, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841029/
https://www.ncbi.nlm.nih.gov/pubmed/36572186
http://dx.doi.org/10.1016/j.jbc.2022.102826
_version_ 1784869742236925952
author Wickramaratne, Anushka
Wickner, Sue
author_facet Wickramaratne, Anushka
Wickner, Sue
author_sort Wickramaratne, Anushka
collection PubMed
description Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative diseases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potential targets for treatments. In the recent JBC Editor’s Pick by Donahue et al., the authors show that diptoindonesin G is a new Hsp90 inhibitor that promotes degradation of the estrogen receptor, an Hsp90 client, without inducing the heat shock response.
format Online
Article
Text
id pubmed-9841029
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-98410292023-01-19 Diptoindonesin G, a new Hsp90 drug Wickramaratne, Anushka Wickner, Sue J Biol Chem Editors' Pick Highlight Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative diseases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potential targets for treatments. In the recent JBC Editor’s Pick by Donahue et al., the authors show that diptoindonesin G is a new Hsp90 inhibitor that promotes degradation of the estrogen receptor, an Hsp90 client, without inducing the heat shock response. American Society for Biochemistry and Molecular Biology 2022-12-23 /pmc/articles/PMC9841029/ /pubmed/36572186 http://dx.doi.org/10.1016/j.jbc.2022.102826 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editors' Pick Highlight
Wickramaratne, Anushka
Wickner, Sue
Diptoindonesin G, a new Hsp90 drug
title Diptoindonesin G, a new Hsp90 drug
title_full Diptoindonesin G, a new Hsp90 drug
title_fullStr Diptoindonesin G, a new Hsp90 drug
title_full_unstemmed Diptoindonesin G, a new Hsp90 drug
title_short Diptoindonesin G, a new Hsp90 drug
title_sort diptoindonesin g, a new hsp90 drug
topic Editors' Pick Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841029/
https://www.ncbi.nlm.nih.gov/pubmed/36572186
http://dx.doi.org/10.1016/j.jbc.2022.102826
work_keys_str_mv AT wickramaratneanushka diptoindonesinganewhsp90drug
AT wicknersue diptoindonesinganewhsp90drug